Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
Business Wire•13/10/2026•06:20 ET
0
Key Highlights
- ➤Q3 reported sales $25.4 billion, up 5.9% year over year
- ➤Q3 adjusted EPS $2.59, down 7.5% year over year
- ➤2026 adjusted EPS guidance raised $0.06 to $11.10 midpoint
- ➤2026 reported sales guidance raised to $101.2 billion midpoint
- ➤FDA authorized OTTAVA as the world’s first table-integrated soft tissue robotic system
Expert Statements
Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson
“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio. In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.”
Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
* 2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%*
Get started
Create a free account to read the full story.